M&A for Medical Peptide and GLP-1 Companies

Buy, sell, or restructure your GLP-1 telehealth platform, peptide clinic, or medspa with regulatory expertise built in.

Medical Peptide M&A Isn’t Like Other Healthcare Deals

FDA & FTC Regulatory Risk
GLP-1 and peptide telehealth platforms face FDA warning letters and enforcement action. Clinics and medspas operate under complex state licensing. Buyers need to know what they’re inheriting. Sellers need protection from post-close liability.

State Medical Board & Physician Licensing
Multi-state operations mean multi-state compliance. CPOM (Collaborative Practice Operating Model) varies by state. Physician credentials, DEA registrations, and medical director relationships don’t always survive ownership changes cleanly.

Supply Chain & Compounding Dependence
Your business depends on compounding pharmacies, raw material suppliers, and manufacturer relationships. Post-close, those contracts may need renegotiation or assignment. Transition risk is real.

Patient Data, Consent Forms & Liability
Who owns patient data post-close? What consent forms did patients sign? Telehealth platforms collect sensitive health information across state lines. This needs to be documented and transferred properly.

What We Bring to Your Medical Peptide Deal

We’re transactional attorneys who built a law firm around healthcare regulatory law—especially the telehealth and compounding subset everyone else gets wrong.

Regulatory Due Diligence

• FDA website and marketing compliance audit (claims, disclaimers, pre-entry gates)
• GLP-1 telehealth warning letter pattern analysis (FDA enforcement waves)
• State medical board compliance by jurisdiction
• Compounding pharmacy audit (CHOW licensing, USP standards)
• Physician credential and DEA registration verification
• CPOM and physician supervision model review

Deal Structuring & Integration

• Corporate structure assessment and optimization
• Post-close remediation playbooks for compliance gaps
• Physician contract and medical director transition planning
• Patient data protection and consent form compliance
• Multi-state licensing transition and medical board notifications
• White-label network and third-party vendor relationship review

Supply Chain & Operational Risk

• Compounding pharmacy agreements and terms review
• Pharmaceutical supplier contracts and transition planning
• Patient data systems and EHR transition planning
• Staff and contractor agreements
• Telehealth platform vendor agreements (licensing, data hosting)

Founder & Operator Perspective

• We’re not just deal lawyers. Our Founding Manager – Dustin Robinson – has founded multiple companies and he’s invested in nearly 20 companies in the healthcare and wellness space. We know what makes or breaks a transaction.
• We integrate AI and automation into our workflows, so we move fast without losing rigor.

Deal Stages We Handle

Pre-Sale Prep
Selling? We audit your compliance posture, identify regulatory red flags, prepare disclosure schedules, and help you understand liability exposure and earnout triggers.

Acquisition Diligence
Buying? Regulatory due diligence memo, risk assessment, FDA enforcement pattern analysis, and recommendations on reps/warranties, indemnities, and earnout claws.

Deal Documentation
Purchase agreement, disclosure schedules, physician transition agreements, compounding pharmacy assignment letters, and multi-state compliance opinions.

Post-Close Integration
Compliance remediation, patient data transition, physician credentialing under new ownership, compounding pharmacy transitions, and regulatory update rollouts.

We Know These Models

GLP-1 Telehealth Platforms
Direct-to-consumer weight loss. CPOM structures, physician partnerships, compounding relationships, and FDA enforcement navigation.

Medical Peptide Clinics
In-person and hybrid peptide therapy (BPC-157, TB-500, AOD-9604, etc.). Medical director oversight, state licensing, patient records management.

Medspas with Peptide Services
Aesthetic practices adding peptide offerings. State medical board compliance, esthetician licensing, physician oversight models.

Hybrid Telehealth & In-Person
Combination models with both remote consultations and in-person treatment centers. Multi-state compliance and operational complexity.

We’ve Advised On

• Telehealth GLP-1 Platform Build: Corporate structure, CPOM compliance, white-label physician network negotiation, and website compliance
• Multi-State Peptide Clinic Expansion: State medical board licensing, physician credentialing, and multi-jurisdictional compliance
• Compounding Pharmacy Relationship Transitions: Agreement renegotiation and supply chain continuity planning
• Patient Data Migration: HIPAA compliance, consent form review, and EHR transition planning
• Physician Contract & Medical Director Transitions: Ensuring continuity of care and regulatory compliance post-acquisition
• Telehealth Platform Integration: Vendor agreement review and technology stack transition

FDA & Regulatory Monitoring

We track FDA enforcement patterns, state medical board actions, and compounding pharmacy regulations. When regulatory changes happen, we help clients understand what they mean for valuations, compliance posture, and deal risk.

Ready to Talk About Your Deal?

Whether you’re buying, selling, or restructuring, start with a regulatory risk roadmap. No obligation.

Schedule a call. Email your deal overview. Meet in person in South Florida or New York.

At LumaLex Law, we help peptide businesses navigate this complex environment with clarity and confidence. Contact us today to learn how we can protect your company and position it for sustainable growth.